News
Novo Nordisk ends Wegovy sales on Hims & Hers over "deceptive marketing" Novo Nordisk said it will stop selling Wegovy on ...
Hims wasn’t stepping back enough from its practice of mass marketing compounded versions of the weight-loss medicine, said ...
Shares in Novo Nordisk fell as much as 3.5% on Monday after detailed trial data on its experimental obesity drug CagriSema ...
Shares of Novo Nordisk (NYSE: NVO) are tumbling on Monday, down 5.6% as of 2:11 p.m. ET. The drop comes as the S&P 500 ...
The achievement of that goal in India, which ranks third in obesity numbers after the US and China, will shatter the record ...
Novo Nordisk said on Monday the European drugs regulator has adopted a positive opinion for an update of the Ozempic label to ...
Meanwhile, Novo had agreed supply deals with Hims and several of its bigger rivals. The idea was to give their existing ...
After consistently failing to meet investor expectations, Novo Nordisk touted a safety profile for CagriSema in line with the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback